Application of humanized mice in the safety experiments of antibody drugs

Abstract

Therapeutic antibodies are valued for their high specificity and selectivity in immunotherapy. However, the potential toxicity they may elicit underscores the necessity of assessing their preclinical efficacy and safety using suitable animal models. In this context, we review the various categories and applications of humanized mice, which have been engrafted with human cells or tissues to mimic the human immune system. These models are extensively utilized in the nonclinical assessment and development of various antibody drugs, acting as a conduit to clinical research. However, several challenges remain, including the limited lifespan of humanized mice, inadequate engraftment of human cells, and the rudimentary nature of the immune environment in these models. The development of humanized immune system models in mice presents both opportunities and challenges, potentially leading to new insights into the evolution and application of antibody therapeutics.

Keywords

antibody drugs / humanized mice / immunogenicity / preclinical evaluation

References

[1] Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020; 25: 4764.

[2] Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol. 2020; 64: 1-12.

[3] Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet. 2019; 34(1): 64-70.

[4] U.S. Food and Drug Administration. Novel Drug Approvals for 2023; 2024. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023

[5] Jawa V, Terry F, Gokemeijer J, et al. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated consensus and review 2020. Front Immunol. 2020; 11: 1301.

[6] Kuramochi T, Igawa T, Tsunoda H, Hattori K. Humanization and simultaneous optimization of monoclonal antibody. Methods Mol Biol. 2019; 1904: 213-230.

[7] Glanz VY, Orekhov AN, Deykin AV. Human disease modelling techniques: current progress. Curr Mol Med. 2018; 18(10): 655-660.

[8] Chuprin J, Buettner H, Seedhom MO, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023; 20(3): 192-206.

[9] Balsa A, Sanmarti R, Rosas J, et al. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. Rheumatology (Oxford). 2018; 57(4): 688-693.

[10] Gorovits B. Current considerations for immunoglobulin isotype characterization of antibody response against biotherapeutics. AAPS J. 2020; 22(6): 144.

[11] Suh K, Kyei I, Hage DS. Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: a review. J Sep Sci. 2022; 45(12): 2077-2092.

[12] Vaisman-Mentesh A, Gutierrez-Gonzalez M, BJ DK, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020; 11: 1951.

[13] Sauna ZE, Richards SM, Maillere B, Jury EC, Rosenberg AS. Editorial: immunogenicity of proteins used as therapeutics. Front Immunol. 2020; 11: 614856.

[14] Garcês S, Demengeot J. The immunogenicity of biologic therapies. Curr Probl Dermatol. 2018; 53: 37-48.

[15] Bonamichi-Santos R, Castells M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. Clin Rev Allergy Immunol. 2018; 54(3): 375-385.

[16] Matucci A, Vultaggio A, Nencini F, Maggi E. Anaphylactic reactions to biological drugs. Curr Opin Allergy Clin Immunol. 2020; 20(4): 346-351.

[17] Hock BD, JL MK, Strother M, Goddard L, Butt L, Currie MJ. Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies. Cancer Immunol Immunother. 2020; 69(12): 2453-2464.

[18] Kichloo A, Albosta M, Dahiya D, et al. Systemic adverse effects and toxicities associated with immunotherapy: a review. World J Clin Oncol. 2021; 12(3): 150-163.

[19] Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023; 129(2): 283-295.

[20] MacLachlan TK, Kronenberg S, Marshall N, et al. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies. Regul Toxicol Pharmacol. 2021; 119: 104825.

[21] Kulikov A, Shipaeva E, Dmitrieva A, et al. Preclinical characterization of a novel anti-cancer PD-L1 inhibitor RPH-120. Front Pharmacol. 2021; 12: 723038.

[22] ICH. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1); 2011. https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf

[23] Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019; 7(6): e00535.

[24] Masemann D, Ludwig S, Boergeling Y. Advances in transgenic mouse models to study infections by human pathogenic viruses. Int J Mol Sci. 2020; 21(23): 9289.

[25] Chen J, Liao S, Xiao Z, et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front Immunol. 2022; 13: 1007579.

[26] Chen J, Liao S, Zhou H, et al. Humanized mouse models of systemic lupus erythematosus: opportunities and challenges. Front Immunol. 2021; 12: 816956.

[27] Holguin L, Echavarria L, Burnett JC. Novel humanized peripheral blood mononuclear cell mouse model with delayed onset of graft-versus-host disease for preclinical HIV research. J Virol. 2022; 96(3): e0139421.

[28] Shu Y, Yue X, Wax J, et al. Both T and B cells are indispensable for the development of a PBMC transfer-induced humanized mouse model for SSc. Arthritis Res Ther. 2022; 24(1): 209.

[29] Yang J, Jiao J, Draheim KM, et al. Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model. FASEB J. 2023; 37(6): e22995.

[30] Rose D, He W, Buetow B, et al. PBMC humanized mouse model with clinial relevance in assessing the safety profile of 4-1BB agonists utomilumab and urelumab. J Immunother Cancer. 2022; 10: A1305.

[31] Cheng L, Ma J, Li G, Su L. Humanized mice engrafted with human HSC only or HSC and thymus support comparable HIV-1 replication, immunopathology, and responses to ART and immune therapy. Front Immunol. 2018; 9: 817.

[32] Matas-Céspedes A, Brown L, Mahbubani KT, et al. Use of human splenocytes in an innovative humanised mouse model for prediction of immunotherapy-induced cytokine release syndrome. Clin Transl Immunol. 2020; 9(11): e1202.

[33] De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018; 39(9): 748-763.

[34] Park N, Pandey K, Chang SK, et al. Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. J Immunother Cancer. 2020; 8(2): e001513.

[35] Luo W, Hoang H, Liao Y, Pan J, Ayello J, Cairo MS. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023; 14: 1277987.

[36] Kozlowska AK, Kaur K, Topchyan P, Jewett A. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice. Cancer Immunol Immunother. 2016; 65(7): 835-845.

[37] Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 2006; 108(2): 487-492.

[38] Kaur K, Jewett A. Differences in tumor growth and differentiation in NSG and humanized-BLT mice; analysis of human vs. humanized-BLT-derived NK expansion and functions. Cancers (Basel). 2022; 15(1): 112.

[39] Kaur K, Chen PC, Ko MW, et al. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in hu-BLT mice. Front Immunol. 2023; 14: 1132807.

[40] Conner CM, van Fossan D, Read K, et al. A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies. Biochem Pharmacol. 2023; 210: 115470.

[41] Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001; 13(12): 1551-1559.

[42] Liu P, Pan Z, Gu C, et al. An omalizumab biobetter antibody with improved stability and efficacy for the treatment of allergic diseases. Front Immunol. 2020; 11: 596908.

[43] Valente D, Mauriac C, Schmidt T, et al. Pharmacokinetics of novel fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models. MAbs. 2020; 12(1): 1829337.

[44] Seckinger A, Majocchi S, Moine V, et al. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers. J Hematol Oncol. 2023; 16(1): 117.

[45] Low BE, Christianson GJ, Lowell E, Qin W, Wiles MV. Functional humanization of immunoglobulin heavy constant gamma 1 fc domain human FCGRT transgenic mice. MAbs. 2020; 12(1): 1829334.

[46] Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11): 786-798.

[47] Ueda O, Wada NA, Kinoshita Y, et al. Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics. Sci Rep. 2017; 7: 45839.

[48] Zhang R, Zhang J, Zhou X, Zhao A, Yu C. The establishment and application of CD3E humanized mice in immunotherapy. Exp Anim. 2022; 71(4): 442-450.

[49] Wang L, Leach V, Muthusamy N, Byrd J, Long M. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment. Blood Adv. 2024; 8(2): 470-481.

[50] Egli J, Heiler S, Weber F, et al. Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice. MAbs. 2022; 14(1): 2143009.

[51] Bessa J, Boeckle S, Beck H, et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res. 2015; 32(7): 2344-2359.

[52] Gupta A, Smith P, Bournazos S, Ravetch JV. A novel mouse strain optimized for chronic human antibody administration. Proc Natl Acad Sci USA. 2022; 119(10): e2123002119.

[53] Aryee KE, Burzenski LM, Yao LC, et al. Enhanced development of functional human NK cells in NOD-scid-IL2rg(null) mice expressing human IL15. FASEB J. 2022; 36(9): e22476.

[54] Katano I, Ito R, Kawai K, Takahashi T. Improved detection of in vivo human NK cell-mediated antibody-dependent cellular cytotoxicity using a novel NOG-FcγR-deficient human IL-15 transgenic mouse. Front Immunol. 2020; 11: 532684.

[55] Rubbert-Roth A, Szabó MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019; 18(12): 102398.

[56] Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(7): 921-926.

[57] Jarczak D, Nierhaus A. Cytokine storm-definition, causes, and implications. Int J Mol Sci. 2022; 23(19): 11740.

[58] Weißmüller S, Kronhart S, Kreuz D, et al. TGN1412 induces lymphopenia and human cytokine release in a humanized mouse model. PLoS ONE. 2016; 11(3): e0149093.

[59] Ye C, Yang H, Cheng M, et al. A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome. FASEB J. 2020; 34(9): 12963-12975.

[60] Yan H, Semple KM, Gonzaléz CM, Howard KE. Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome. Transl Res. 2019; 210: 43-56.

[61] Yan H, Bhagwat B, Sanden D, et al. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models. Toxicol Appl Pharmacol. 2019; 372: 57-69.

[62] Martin GH, Gonon A, Martin-Jeantet P, et al. Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model. Front Immunol. 2024; 15: 1357716.

[63] Roy S, Ayudhya CC, Thapaliya M, Deepak V, Ali H. Multifaceted MRGPRX2: new insight into the role of mast cells in health and disease. J Allergy Clin Immunol. 2021; 148(2): 293-308.

[64] Mencarelli A, Gunawan M, Yong KS, et al. A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions. J Leukoc Biol. 2020; 107(5): 797-807.

[65] Weaver JL, Zadrozny LM, Gabrielson K, Semple KM, Shea KI, Howard KE. BLT-immune humanized mice as a model for nivolumab-induced immune-mediated adverse events: comparison of the NOG and NOG-EXL strains. Toxicol Sci. 2019; 169(1): 194-208.

[66] Lavender KJ, Pang WW, Messer RJ, et al. BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood. 2013; 122(25): 4013-4020.

[67] Hess NJ, Brown ME, Capitini CM. GVHD pathogenesis, prevention and treatment: lessons from humanized mouse transplant models. Front Immunol. 2021; 12: 723544.

[68] Di Y, Lavender KJ. Inducing long-term HIV-1 latency in the TKO-BLT mouse model. Methods Mol Biol. 2022; 2407: 253-273.

[69] Yaguchi T, Kobayashi A, Inozume T, et al. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol. 2018; 15(11): 953-962.

[70] Brehm MA, Kenney LL, Wiles MV, et al. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J. 2019; 33(3): 3137-3151.

[71] Ka Y, Katano I, Nishinaka E, et al. Improved engraftment of human peripheral blood mononuclear cells in NOG MHC double knockout mice generated using CRISPR/Cas9. Immunol Lett. 2021; 229: 55-61.

[72] Tan S, Fang M, Fan W, et al. Improvement of human myeloid and natural killer cell development in humanized mice via hydrodynamic injection of transposon plasmids containing multiple human cytokine genes. Immunol Cell Biol. 2022; 100(8): 624-635.

[73] Zhang T, Liu W, Yang YG. B cell development and antibody responses in human immune system mice: current status and future perspective. Sci China Life Sci. 2024; 67(4): 645-652.

[74] Matsuda M, Ono R, Iyoda T, et al. Human NK cell development in hIL-7 and hIL-15 knockin NOD/SCID/IL2rgKO mice. Life Sci Alliance. 2019; 2(2): e201800195.

[75] Nikzad R, Angelo LS, Aviles-Padilla K, et al. Human natural killer cells mediate adaptive immunity to viral antigens. Sci Immunol. 2019; 4(35): eaat8116.

[76] Abeynaike SA, Huynh TR, Mehmood A, et al. Human hematopoietic stem cell engrafted IL-15 transgenic NSG mice support robust NK cell responses and sustained HIV-1 infection. Viruses. 2023; 15(2): 365.

[77] Iwabuchi R, Ikeno S, Kobayashi-Ishihara M, et al. Introduction of human Flt3-L and GM-CSF into humanized mice enhances the reconstitution and maturation of myeloid dendritic cells and the development of Foxp3(+)CD4(+) T cells. Front Immunol. 2018; 9: 1042.

[78] Katti A, Vega-Pérez A, Foronda M, et al. Generation of precision preclinical cancer models using regulated in vivo base editing. Nat Biotechnol. 2024; 42(3): 437-447.

[79] Avery LB, Wang M, Kavosi MS, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016; 8(6): 1064-1078.

[80] Zeleniak A, Wiegand C, Liu W, et al. De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids. Nat Methods. 2022; 19(10): 1306-1319.

[81] Gao J, Miao J, Sun H, et al. TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice. Front Immunol. 2022; 13: 955812.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.